December 23, 2020 -- Compugen announced it is entitled to receive $2 million upon reaching the first preclinical milestone in an ongoing license agreement with AstraZeneca for the development of antibody products.
Under the deal, AstraZeneca received an exclusive license for the development of bispecific and multispecific antibody products based on one of Compugen's pipeline programs.
Compugen received a $10 million upfront payment and is eligible to receive up to $200 million in development, regulatory, and commercial milestones for the first product, as well as tiered royalties on future product sales, the company said.